21 March 2011 in Minimally Invasive Therapy & Allied Technologies
MMMartin Marcynski-Bühlow
+2
To date, transcatheter valve implantation is limited to the replacement of pulmonary and aortic valves. The aim of this study was to analyze a valved stent for minimally invasive implantation in the mitral position. A self-expanding mitral valved stent was designed for transapical implantation. Thirty pigs underwent off-pump mitral valved stent implantation with follow-up times of 60 minutes (n = 17) and seven days (n = 13). Transesophageal echocardiography and computed tomography were used to evaluate stent function and positioning. After valved stent deployment, accurate adjustment of the intra-annular position reduced paravalvular leakage in all animals. Accurate positioning was established in all but five animals. The average mean transvalvular gradient across the mitral valve and the left ventricular outflow tract recorded immediately after deployment, six hours and one week were 1.85 ± 0.95 mmHg, 3.45 ± 1.65 mmHg, 4.15 ± 2.3 mmHg and 1.35 ± 1.35 mmHg, 1.45 ± 0.7 mmHg, 1.9 ± 0.65 mmHg, respectively. No valved stent migration, embolization, systolic anterior movement or left ventricular outflow tract obstruction was observed. The mitral valved stent can be deployed in a reproducible manner to achieve reliable stent stability, minimal gradients across the left ventricular outflow tract and adequate stent function in acute and short term experimental settings.
1 July 2014 in EuroIntervention
MMMartin Marczynski-Bühlow
+2
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
29 July 2016 in European Journal of Cardio-Thoracic Surgery
OBJECTIVES A large cohort of patients suffering from severe mitral regurgitation does not meet the indications for conventional surgery and would greatly benefit from a transcatheter approach in the beating heart. Consequently, off-pump transcatheter mitral valve procedures have been the focus of recent research. The aim of this study was the in vivo evaluation and comparison of subannular versus apical fixation of mitral valved stents to show the feasibility of subannular anchorage. METHODS Twenty-two pigs received a self-expanding valved stent in the mitral position in an off-pump procedure. The first design (design AP: n = 12) was anchored apically and served as the control group. The second design (design SA: n = 10) included additional sub-annular fixation elements. Echocardiographic and haemodynamic evaluations were conducted before and 1 h after stent implantation. RESULTS Haemodynamic stability was achieved, and the capillary wedge pressure was within a normal range (AP: 11 ± 4 mmHg, SA: 9 ± 4 mmHg). Paravalvular leakages were trace or less in 19 of 20 cases. The mean gradients across the valved stent increased (P ≤ 0.014) but remained within a physiological range in both groups (AP: 1.2 ± 0.6 mmHg, SA: 2.6 ± 2.0 mmHg). The longitudinal heart function remained within a physiological normal range (AP: 0.95 ± 0.1 cm, SA: 0.95 ± 0.1 cm) but was reduced in group SA. The ejection fraction decreased after stent implantation (AP: 52 ± 10%, SA: 48 ± 4%). The mean survival time was higher in group AP compared with group SA. CONCLUSIONS The proof-of-principle for the subannular fixation was shown with haemodynamic stability, low gradients and physiological longitudinal function. A decreased ejection fraction, survival time and fractures identify potential areas for improvement. With regard to the long-term outcome, the group with subannular fixation did not reach the results of the group with apical fixation in this study.
22 December 2016 in Kardiologie up2date
An increasing number of patients suffering of symptomatic mitral regurgitation (MR) cannot be treated with conventional surgical methods due to multiple comorbidities and advanced age. Therefore, the development of transcatheter techniques for treatment of MR in the beating heart is focus of recent research. An overview of the different repair technologies according to the anatomical target and replacement technologies (transcatheter mitral valved stents) is presented.